Clinical Trial Update: Ultra-low Dose Bevacizumab Plus Temozolomide for Recurrent High-grade Gliomas [NA]

View source ↗

Summary

This document updates a clinical trial of ultra-low-dose bevacizumab plus temozolomide for recurrent high-grade glioma; the record lists no phase or status info…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• High-grade Glioma

Drugs mentioned

• Avastin (bevacizumab)
• Temodar (Temozolomide)

Snippet

Sponsor: Hebei Yanda Hospital | Conditions: Recurrent High-grade Glioma | NA | Status: UNKNOWN